London-based generic drug maker Hikma Pharmaceuticals has announced a four-year partnership with Direct Relief that includes a commitment of funding and the provision of medications for vulnerable populations, with a focus on the United States and Jordan.
The arrangement includes support for Direct Relief's network of safety-net providers and will include the provision of funding, pharmaceuticals, technology, training, and volunteers. In the U.S., the focus will be on supporting the medical relief organization's network of community health centers and pharmacies, which cater to underinsured and uninsured individuals in need of acute and chronic medical care in states where the majority of Hikma's employees live — New Jersey, Ohio, and Pennsylvania. In Jordan, Direct Relief will provide essential medicines, supplies, and other resources to individuals in refugee camps, as well as a telemedicine unit to assist physicians faced with difficult cases.
"Ensuring that our products are available and accessible to those that need them is the essence of our brand promise and has been our purpose for the past forty years," said Hikma executive chairman Said Darwazah. "Our vision is for a healthier world, and we are very proud to be embarking on this important partnership with Direct Relief to help both their network of community clinics and pharmacies in the U.S., as well as providing critical medical care to refugees in Jordan."